Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#140 of 388

Josh Schimmer

Cantor Fitzgerald · Equity Research Analyst
ProvisionalRating since 2023No new ratings since Jul 2025

Analyst rating accuracy & track record

Josh Schimmer is an equity research analyst at Cantor Fitzgerald. Quantellect has scored 24 of their stock calls across 13 companies. Their picks beat their sector 38% of the time over the next 12 months, and their price targets were reached of the time within a year.

Win % vs sector
38%
PT Hit % (12mo)
Avg sector-excess
−2.4%
Scored calls
24
Tickers
13
Tier
Provisional

Track record

Quantellect has scored 24 of Josh Schimmer's stock calls across 13 companies, dating back to 2023. Their rated stocks beat their own sector 38% of the time over the next 12 months. On a typical call, a Schimmer pick returned −2.4% more than its sector over the following year.

Of the scored calls, 24 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
TRVITrevi Therapeutics Inc
Buy$25.00Jul 2025+175.1%Miss
CMPSCompass Pathways Plc
Buy$12.00May 2025+165.6%Hit
RCKTRocket Pharmaceuticals Inc
Buy$30.00May 2025−62.8%Miss
SEPNSepterna, Inc. Common Stock
Buy$25.00May 2025+153.4%Hit
CGONCG Oncology, Inc. Common stock
Buy$75.00Apr 2025+138.2%Miss
AARDAardvark Therapeutics, Inc. Common Stock
Buy$50.00Apr 2025−60.5%Miss
ARTVArtiva Biotherapeutics, Inc. Common Stock
Buy$20.00Mar 2025+47.2%Miss
AARDAardvark Therapeutics, Inc. Common Stock
Buy$50.00Mar 2025−51.1%Miss
SEPNSepterna, Inc. Common Stock
Buy$50.00Feb 2025+123.6%Miss
SEPNSepterna, Inc. Common Stock
Buy$50.00Nov 2024−5.9%Miss
ZURAZura Bio Limited Class A Ordinary Shares
BuyOct 2024−27.6%
SPRYARS Pharmaceuticals, Inc
Buy$30.00Oct 2024−14.9%Miss
ALECAlector Inc
BuySep 2024−37.5%
SPRYARS Pharmaceuticals, Inc
Buy$30.00Sep 2024−17.4%Miss
ALECAlector Inc
BuySep 2024−42.0%
SPRYARS Pharmaceuticals, Inc
Buy$30.00Sep 2024−0.8%Miss
ANNXAnnexon Inc
BuySep 2024−56.6%
ARCTArcturus Therapeutics Holdings Inc
BuySep 2024+0.3%
SPRYARS Pharmaceuticals, Inc
Buy$30.00Aug 2024+18.6%Miss
ZURAZura Bio Limited Class A Ordinary Shares
BuyAug 2024−40.0%
ARTVArtiva Biotherapeutics, Inc. Common Stock
Buy$23.00Aug 2024−66.0%Miss
ZURAZura Bio Limited Class A Ordinary Shares
BuyJun 2024−59.2%
ZURAZura Bio Limited Class A Ordinary Shares
BuyJun 2024−62.6%
XENEXenon Pharmaceuticals Inc
BuyOct 2023+5.7%
Go to

Josh Schimmer: analyst track record FAQ

Is Josh Schimmer a good stock analyst?

Yes, by track record. Josh Schimmer ranks number 140 of 388 of the analysts Quantellect scores, with a Q Score of 43 out of 100. Past results do not guarantee future ones.

What is Josh Schimmer's win rate?

Josh Schimmer's win rate is 38%. Across 24 scored calls, their rated stocks beat their sector 38% of the time over the next 12 months. On a typical call they returned −2.4% more than the sector.

What stocks and sectors does Josh Schimmer cover?

Josh Schimmer covers 13 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Josh Schimmer's price targets accurate?

Josh Schimmer's price targets are reached within 12 months — of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Josh Schimmer's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Josh Schimmer rank among Wall Street analysts?

Josh Schimmer ranks number 140 of 388 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.